Groundbreaking findings from the landmark CLEAR (Clinical trial Comparing Lenvatinib with Ecerolimus or Pembrolizumab in ...

Researchers at Vilnius University have developed an effective approach to liquid biopsy that contributes to the field of ...

In a small clinical trial of nine patients with stage III and IV kidney cancer, a personalized anti-tumor vaccine generated ...

Dr. Catherine Wu discussed the unique aspects of clear cell renal cell carcinoma and the challenges of targeting it with a ...

For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug called Pembrolizumab (Keytruda).

A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...

All nine patients treated with a personalized cancer vaccine following removal of their tumors remained cancer-free at a median data cut-off of 34.7 months.

Neoantigen-targeting PCVs are highly immunogenic in high-risk clear cell RCC and can target key driver mutations and induce antitumor immunity.

A new personalized cancer vaccine has shown encouraging results in preventing the return of kidney cancer after surgery.

Immune therapy has transformed how cancer is treated, but many tumors continue to evade these treatments, thanks to their resemblance to healthy tissue.

The Odessa American is the leading source of local news, information, entertainment and sports for the Permian Basin.

Africa Studio – stock.adobe.com For most stage 3 or 4 kidney cancer patients, the standard treatment is surgical removal of the tumor, which is often followed by an immunotherapy drug called Pem ...